SCHEMBL5386367

SCHEMBL5386367

CC(C)c1nsc(NS(=O)(=O)c2cccc(F)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
AADAT Q8N5Z0 1/20 0.44
ALDH1A1 P00352 1/20 0.43
BRAF P15056 2/20 0.42
PGR P06401 1/20 0.41
FSCN1 Q16658 1/20 0.41
GBA1 P04062 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HSPD1 P10809 2/20 0.40
PTPN2 P17706 2/20 0.40
PTPN1 P18031 2/20 0.40
PTPN5 P54829 2/20 0.40
HSPE1 P61604 2/20 0.40
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5404427 0.84 MEN1 (0.54) SCN9APGRKMT2A
SCHEMBL5391600 0.84 SCN9A (0.50) SCN9AALDH1A1KMT2A
SCHEMBL1094819 0.83 L3MBTL1 (0.55) SCN9AL3MBTL1AADATALDH1A1PGR
SCHEMBL5399376 0.82 SCN9A (0.56) SCN9AL3MBTL1ALDH1A1PGRKMT2A
SCHEMBL5395224 0.82 SCN9A (0.56) SCN9APGRMAPTHSPD1PTPN2
SCHEMBL5391569 0.82 SLC40A1 (0.51) SCN9ABRAF
SCHEMBL5397862 0.81 LMNA (0.55) SCN9AL3MBTL1ALDH1A1FSCN1MAPT
SCHEMBL5396289 0.81 SCN9A (0.42) SCN9ABRAFPIK3CA
SCHEMBL5391554 0.81 SCN9A (0.48) SCN9AALDH1A1MAPTKMT2A
SCHEMBL5401411 0.80 POLB (0.44) SCN9APOLBPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 SCN9A 1476/4885L3MBTL1 4378/4885AADAT 1579/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 SCN9A 1829/4885L3MBTL1 4720/4885AADAT 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.